Publication:
Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis

Simple item page
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorsYilmaz-Oner, Sibel; Ozen, Gulsen; Can, Meryem; Atagunduz, Pamir; Direskeneli, Haner; Inanc, Nevsun
dc.date.accessioned2022-03-13T12:47:04Z
dc.date.available2022-03-13T12:47:04Z
dc.date.issued2015
dc.description.abstractObjective. Remission is the primary aim in the treatment of patients with rheumatoid arthritis (RA). In this study, we aimed to evaluate biomarker profiles of patients in remission by different criteria and compare these profiles with controls. Methods. Serum levels of calprotectin, interleukin 6 (IL-6), type II collagen helical peptide, C-terminal crosslinking telopeptide of type I collagen generated by matrix metalloproteinases (ICTP), matrix metalloproteinase 3 (MMP-3), resistin, and leptin were measured by ELISA in 80 patients. The patients were in Disease Activity Score at 28 joints with erythrocyte sedimentation rate (DAS28-ESR) remission, and had these characteristics: female/male 54/26, mean age 51.4 +/- 12.1 years, mean disease duration 11.4 +/- 8.1 years, rheumatoid factor positivity 68.7% (n = 55), anticyclic citrullinated peptide positivity 60.7% (n = 48). These patients were also evaluated for the American College of Rheumatology/European League Against Rheumatism (Boolean) and Simple Disease Activity Index (SDAI) remissions. Additionally, 80 age-, sex-, and comorbidity-matched individuals without rheumatic diseases were included in the study as controls. Results. At recruitment of 80 patients in DAS28 remission, 33 patients (41.2%) were found in Boolean remission and 39 patients (48.7%) were in SDAI remission. Serum MMP-3, ICTP, resistin, and IL-6 levels of the 80 patients in DAS28 remission were statistically significantly higher than the controls. Patients in Boolean and SDAI remissions had significantly higher serum ICTP, resistin, and IL-6 levels in comparison with the controls. Conclusion. The 3 commonly used remission criteria of RA are almost similar with regard to patients' biomarker levels. Biomarker profiles of patients may provide complementary information to clinical evaluation of remission and may help to determine the patients under the risk of progression.
dc.identifier.doi10.3899/jrheum.150478
dc.identifier.eissn1499-2752
dc.identifier.issn0315-162X
dc.identifier.pubmed26472417
dc.identifier.urihttps://hdl.handle.net/11424/238019
dc.identifier.wosWOS:000365221400011
dc.language.isoeng
dc.publisherJ RHEUMATOL PUBL CO
dc.relation.ispartofJOURNAL OF RHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRHEUMATOID ARTHRITIS
dc.subjectBIOMARKERS
dc.subjectREMISSION CRITERIA
dc.subjectI COLLAGEN DEGRADATION
dc.subjectDISEASE-ACTIVITY
dc.subjectSERUM-LEVELS
dc.subjectCLINICAL REMISSION
dc.subjectSYNOVITIS
dc.subjectCARTILAGE
dc.subjectRECEPTOR
dc.subjectLEPTIN
dc.subjectOSTEOARTHRITIS
dc.subjectINTERLEUKIN-6
dc.titleBiomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis
dc.typearticle
dspace.entity.typePublication
local.avesis.idb732a15b-1e3c-48ed-9e63-20b77a889e6c
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages5
oaire.citation.endPage2070
oaire.citation.issue11
oaire.citation.startPage2066
oaire.citation.titleJOURNAL OF RHEUMATOLOGY
oaire.citation.volume42
relation.isAuthorOfPublication07a34d26-21f3-475d-bd36-152d6c659370
relation.isAuthorOfPublication.latestForDiscovery07a34d26-21f3-475d-bd36-152d6c659370

Files

Collections

Research Outputs